Drug Trial Radar · NCT01516307
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
Last checked: Nov 19, 2026Latest source record: Sep 16, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
349
Actual
Start
Dec 2011
Primary completion
Aug 2016
Study completion Aug 2019
Sponsor
- Lead sponsor
- OBI Pharma, IncIndustry
- Sponsor type
- Industry
- First posted
- Jan 24, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare active immunotherapy (OPT-822/OPT-821) with PBS in combination with low dose cyclophosphamide, in post-treated metastatic breast cancer subjects with stable disease or response to treatment.
Conditions
- Metastatic Breast Cancer
Interventions
OPT-822/OPT-821(30 μg/100 μg)Biological
Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37. OPT-822 and OPT-821 are combined at time of injection.
Phosphate Buffer Saline (PBS)Biological
Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37.
CyclophosphamideDrug
Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: Progression or up to 2 years
Locations
43 sites in 5 countries. Site status is shown where the registry gives one.
The University of Alabama at Birmingham (UAB)
Birmingham, Alabama
St. Jude Heritage Healthcare, Virginia K. Crosson Cancer Center
Fullerton, California
University of California, San Diego (UCSD)
La Jolla, California
University of California, Irvine (UCI)
Orange, California
University of California, San Francisco (UCSF)
San Francisco, California
Coastal Integrative Cancer Care
San Luis Obispo, California
Central Coast Medical Oncology Corporation
Santa Maria, California
University of California, Los Angeles (UCLA)
Santa Monica, California
Memorial Regional Hospital
Hollywood, Florida
University of Chicago Medical Center
Chicago, Illinois
Weill Cornell Medical College
New York, New York
Hope Women's Cancer Center
Asheville, North Carolina
University of Texas MD Anderson Cancer Center
Houston, Texas
UNIMED Medical Institute
Hong Kong, China
HCG, Bangalore Institute of Oncology
Bengaluru, India
Curie Manavata Cancer Centre
Mumbai, India
Dong-A University Hospital
Busan, South Korea
Pusan National University Hospital
Busan, South Korea
Inha University Hospital
Chungcheongbuk-Do, South Korea
National Cancer Center
Chungcheongbuk-Do, South Korea
Kyungpook National University Medical Center
Daegu, South Korea
Yeungnam University Medical Center
Daegu, South Korea
Asan Medical Center
Seoul, South Korea
Korea University Anam Hospital
Seoul, South Korea
Seoul National University Hospital ,
Seoul, South Korea
Seoul St. Mary's Hospital
Seoul, South Korea
Severance Hospital
Seoul, South Korea
Changhua Christian Hospital
Changhua, Taiwan
Chang Gung Memorial Hospital-KS
Kaohsiung City, Taiwan
Kaohsiung Medical University Hospital
Kaohsiung City, Taiwan
Kaohsiung Veterans General Hospital
Kaohsiung City, Taiwan
Chang Gung Memorial Hospital -Linkou
Linkou District, Taiwan
Mackay Memorial Hospital
New Taipei City, Taiwan
China Medical University Hospital
Taichung, Taiwan
Taichung Veterans General Hospital
Taichung, Taiwan
Chi Mei Medical Center
Tainan, Taiwan
National Cheng Kung University Hospital
Tainan, Taiwan
Chang Gung Memorial Hospital-Taipei
Taipei, Taiwan
Koo Foundation Sun Yat-Sen Cancer Center
Taipei, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.